Literature DB >> 25041037

Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome.

Ming-Hui Chen1, Joseph G Ibrahim, Donglin Zeng, Kuolung Hu, Catherine Jia.   

Abstract

In many biomedical studies, patients may experience the same type of recurrent event repeatedly over time, such as bleeding, multiple infections and disease. In this article, we propose a Bayesian design to a pivotal clinical trial in which lower risk myelodysplastic syndromes (MDS) patients are treated with MDS disease modifying therapies. One of the key study objectives is to demonstrate the investigational product (treatment) effect on reduction of platelet transfusion and bleeding events while receiving MDS therapies. In this context, we propose a new Bayesian approach for the design of superiority clinical trials using recurrent events frailty regression models. Historical recurrent events data from an already completed phase 2 trial are incorporated into the Bayesian design via the partial borrowing power prior of Ibrahim et al. (2012, Biometrics 68, 578-586). An efficient Gibbs sampling algorithm, a predictive data generation algorithm, and a simulation-based algorithm are developed for sampling from the fitting posterior distribution, generating the predictive recurrent events data, and computing various design quantities such as the type I error rate and power, respectively. An extensive simulation study is conducted to compare the proposed method to the existing frequentist methods and to investigate various operating characteristics of the proposed design.
© 2014, The International Biometric Society.

Entities:  

Keywords:  Clinical trial design; Gibbs sampling; Myelodysplastic syndrome; Power prior; Recurrent events; Type I error rate and power

Mesh:

Year:  2014        PMID: 25041037      PMCID: PMC4276515          DOI: 10.1111/biom.12215

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  12 in total

1.  Sample size calculations for the two-sample problem using the multiplicative intensity model.

Authors:  M V Bernardo; D P Harrington
Journal:  Stat Med       Date:  2001-02-28       Impact factor: 2.373

2.  Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.

Authors:  Joseph G Ibrahim; Ming-Hui Chen; H Amy Xia; Thomas Liu
Journal:  Biometrics       Date:  2011-09-28       Impact factor: 2.571

3.  Sample size calculations for comparative clinical trials with over-dispersed Poisson process data.

Authors:  Shigeyuki Matsui
Journal:  Stat Med       Date:  2005-05-15       Impact factor: 2.373

4.  Power considerations for clinical trials using multivariate time-to-event data.

Authors:  M D Hughes
Journal:  Stat Med       Date:  1997-04-30       Impact factor: 2.373

5.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

Authors:  Luca Malcovati; Matteo Giovanni Della Porta; Cristiana Pascutto; Rosangela Invernizzi; Marina Boni; Erica Travaglino; Francesco Passamonti; Luca Arcaini; Margherita Maffioli; Paolo Bernasconi; Mario Lazzarino; Mario Cazzola
Journal:  J Clin Oncol       Date:  2005-09-26       Impact factor: 44.544

6.  Multivariate recurrent events in the presence of multivariate informative censoring with applications to bleeding and transfusion events in myelodysplastic syndrome.

Authors:  Donglin Zeng; Joseph G Ibrahim; Ming-Hui Chen; Kuolung Hu; Catherine Jia
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

7.  The design and analysis of randomized trials with recurrent events.

Authors:  R J Cook
Journal:  Stat Med       Date:  1995-10-15       Impact factor: 2.373

8.  Bayesian design of noninferiority trials for medical devices using historical data.

Authors:  Ming-Hui Chen; Joseph G Ibrahim; Peter Lam; Alan Yu; Yuanye Zhang
Journal:  Biometrics       Date:  2011-03-01       Impact factor: 2.571

9.  Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models.

Authors:  Brian P Hobbs; Daniel J Sargent; Bradley P Carlin
Journal:  Bayesian Anal       Date:  2012-08-28       Impact factor: 3.728

10.  Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

Authors:  Lewis R Silverman; David R McKenzie; Bercedis L Peterson; James F Holland; Jay T Backstrom; C L Beach; Richard A Larson
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

View more
  6 in total

1.  Bayesian clinical trial design using historical data that inform the treatment effect.

Authors:  Matthew A Psioda; Joseph G Ibrahim
Journal:  Biostatistics       Date:  2019-07-01       Impact factor: 5.899

2.  Bayesian design of biosimilars clinical programs involving multiple therapeutic indications.

Authors:  Matthew A Psioda; Kuolung Hu; Yang Zhang; Jean Pan; Joseph G Ibrahim
Journal:  Biometrics       Date:  2019-11-11       Impact factor: 2.571

3.  Bayesian Design of Non-Inferiority Clinical Trials via the Bayes Factor.

Authors:  Wenqing Li; Ming-Hui Chen; Xiaojing Wangy; Dipak K Dey
Journal:  Stat Biosci       Date:  2017-07-06

4.  The power prior: theory and applications.

Authors:  Joseph G Ibrahim; Ming-Hui Chen; Yeongjin Gwon; Fang Chen
Journal:  Stat Med       Date:  2015-09-07       Impact factor: 2.373

5.  Bayesian design of a survival trial with a cured fraction using historical data.

Authors:  Matthew A Psioda; Joseph G Ibrahim
Journal:  Stat Med       Date:  2018-06-25       Impact factor: 2.373

6.  Bayesian selective response-adaptive design using the historical control.

Authors:  Mi-Ok Kim; Nusrat Harun; Chunyan Liu; Jane C Khoury; Joseph P Broderick
Journal:  Stat Med       Date:  2018-06-13       Impact factor: 2.373

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.